Health plans sold through Iowa’s Farm Bureau will ask applicants if they have any pre-existing conditions, and some applicants could be denied coverage based on their answers; Congress this week approved rare bipartisan legislation aimed at curbing opioid use disorder, giving lawmakers something to campaign on ahead of the November midterms; a new study sought to assess the cost to produce insulin and to examine how biosimilar insulin, if manufactured on a large scale, could reduce the cost of treatment for patients with diabetes.
Health plans sold through Iowa’s Farm Bureau will ask applicants if they have any pre-existing conditions, and some applicants could be denied coverage based on their answers, The Hill reported. According to a checklist posted online by the Farm Bureau, applicants will be asked about a list of conditions related to mental health, blood pressure, the reproductive system, and lungs or the respiratory system, among others. If an applicant says they have been treated for any of 16 conditions in the past 5 years, they will be required to provide detailed explanations of the treatments, medications, and current status. The plans were made legal under a law signed by Iowa Republican Governor Kim Reynolds in April. The plans are expected to be much cheaper than plans sold on the state’s Affordable Care Act exchange because they don’t have to meet federal requirements.
Congress this week approved rare bipartisan legislation aimed at curbing opioid use disorder, giving lawmakers something to campaign on ahead of the November midterms, the Associated Press reported. The Support for Patients and Communities Act passed the Senate 98-1 Wednesday and the House 393-8 last week. The measure attacks the problem in hundreds of ways; among other provisions, it will allow physician assistants and nurse practitioners to prescribe medication-assisted treatment, and it will broaden coverage under Medicaid and Medicare.A new study sought to assess the cost to produce insulin and to examine how biosimilar insulin, if manufactured on a large scale, could reduce the cost of treatment for patients with diabetes, The Center for Biosimiliars reported. The investigators designed formulae for estimating competitive—but profitable—prices for biosimilar insulin using the cost of an active pharmaceutical ingredient and excipients either exported from India or based on quotes from biosimilar manufacturers, the cost of formulation into vials, development and regulatory costs, and a margin for operating expenses and profit. Despite the fact that insulin is indispensable for approximately 100 million people with diabetes worldwide, an estimated half of those patients have no reliable supply of insulin, due in large part to cost.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More